Chronic obstructive pulmonary disease MedDRA version: 21.1 Level: PT Classification code 10009033 Term: Chronic obstructive pulmonary disease System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders
Conditions
Interventions
Product Name: Dupilumab
Product Code: SAR231893
Pharmaceutical Form: Solution for injection in pre-filled syringe
INN or Proposed INN: Dupilumab
Current Sponsor code: SAR231893
Other descriptive name:
Sponsors
Sanofi-aventis Recherche & Développement
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: - Participants with a physician diagnosis of COPD who meet the following criteria at screening: - Current or former smokers with a smoking history of =10 pack-years. - Moderate-to-severe COPD (post-bronchodilator FEV1/ forced vital capacity [FVC]ratio 30% and =70%). - Medical Research Council (MRC) Dyspnea Scale grade =2. - Patient-reported history of signs and symptoms of chronic bronchitis (chronic productive cough) for 3 months in the year up to screening in the absence of other known causes of chronic cough. - Documented history of high exacerbation risk defined as exacerbation history of =2 moderate or =1 severe within the year prior to inclusion. At least one exacerbation should have occurred while the patient was taking inhaled corticosteroid (ICS)/long acting beta agonist (LABA)/long acting muscarinic antagonist (LAMA) (or LABA/LAMA if ICS is contraindicated). Moderate exacerbations are recorded by the investigator and defined as AECOPD that require either systemic corticosteroids (intramuscular, intravenous, or oral) and/or antibiotics. One of the two required moderate exacerbations has to require the use of systemic corticosteroids. Severe exacerbations are recorded by the investigator and defined as AECOPD requiring hospitalization or observation > 24 hours in emergency department/urgent care facility. - Background triple therapy (ICS + LABA + LAMA) for 3 months prior to randomization with a stable dose of medication for =1 month prior to Visit 1; Double therapy (LABA + LAMA) allowed if ICS is contraindicated. - Evidence of Type 2 inflammation: Patients with blood eosinophils =300 cells/microliter at Visit 1. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 2333 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 747
Exclusion criteria
Exclusion criteria: - COPD diagnosis for less than 12 months prior to randomization. - Participants with current diagnosis of asthma according to the Global Initiative for Asthma (GINA) guidelines, or documented history of asthma. - Significant pulmonary disease other than COPD (e.g., lung fibrosis, sarcoidosis, interstitial lung disease, pulmonary hypertension, bronchiectasis, Churg-Strauss Syndrome etc) or another diagnosed pulmonary or systemic disease associated with elevated peripheral eosinophil counts. - Cor pulmonale, evidence of right cardiac failure. - Long-term treatment with oxygen >4.0 L/min OR if a participant requires more than 2.0 L/min in order to maintain oxygen saturation >88%. - Hypercapnia requiring Bi-level ventilation. - AECOPD as defined in inclusion criteria within 4 weeks prior to screening, or during the screening period. - Respiratory tract infection within 4 weeks prior to screening, or during the screening period. - History of, or planned pneumonectomy or lung volume reduction surgery. Patients who are participating in the acute phase of a pulmonary rehabilitation program, ie, who started rehabilitation <4 weeks prior to screening (Note: patients in the maintenance phase of a rehabilitation program can be included). - Diagnosis of a-1 anti-trypsin deficiency.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: To evaluate the efficacy of dupilumab administered every 2 weeks in patients with moderate or severe Chronic Obstructive Pulmonary Disease (COPD) as measured by - Annualized rate of acute moderate or severe COPD exacerbation (AECOPD) ;Secondary Objective: - To evaluate the effect of dupilumab administered every 2 weeks on - Pre-bronchodilator forced expiratory volume in 1 second (FEV1) over 12 weeks compared to placebo - Health related quality of life, assessed by the change from baseline to Week 52 in the St. George’s Respiratory Questionnaire (SGRQ) - Pre-bronchodilator FEV1 over 52 weeks compared to placebo - Lung function assessments - Moderate and severe COPD exacerbations - To evaluate safety and tolerability - To evaluate dupilumab systemic exposure and incidence of antidrug antibodies (ADA);Primary end point(s): Annual rate of acute COPD exacerbation (AECOPD) ; Annualized rate of moderate or severe COPD exacerbations over the 52-week treatment period compared to placebo;Timepoint(s) of evaluation of this end point: Baseline to week 52 | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary end point(s): 1 - Change in pre-bronchodilator FEV1 ; Change in pre-bronchodilator FEV1 from baseline to Week 12 compared to placebo 2 - Change in SGRQ ; Change from baseline to Week 52 in SGRQ total score compared to placebo 3 - Improvement in SGRQ ; Proportion of patients with SGRQ improvement =4 points at Week 52 4 - Change in pre-bronchodilator FEV1 from baseline to Week 52 ; Change in pre-bronchodilator FEV1 from baseline to Week 52 compared to placebo 5 - Change in pre-bronchodilator FEV1 from baseline to time points up to Week 44 ; Change in pre-bronchodilator FEV1 from baseline to weeks other than 12 and 52 (i.e. Weeks 2, 4, 8, 24, 36 and 44) compared to placebo 6 - Change in post-bronchodilator FEV1 lung function ; Change in post-bronchodilator FEV1 from baseline at Weeks 2, 4, 8, 12, 24, 36 and 52 compared to placebo 7 - Change in forced expiratory flow (FEF) 25-75% ; Change in FEF 25-75% from baseline to Weeks 2, 4, 8, 12, 24, 36, 44 and 52 8 - Annualized rate of severe AECOPD ; Annualized rate of severe COPD exacerbations compared to placebo over the 52-week treatment period 9 - Time to first AECOPD ; Time to first moderate or severe COPD exacerbation compared with placebo during the 52-week treatment period 10 - Adverse events ; Number of adverse events (AEs)/treatment-emergent adverse events (TEAEs) 11 - Potentially clinically significant abnormality (PCSA) in laboratory tests ; Percentage of patients with at least one incidence of PCSA 12 - Anti-drug antibodies ; Incidence of anti-drug antibodies against dupilumab;Timepoint(s) of evaluation of this end point: 1 : Baseline to week 12 2, 3, 4, 8, 9 : Baseline to week 52 5 : Baseline to weeks 2, 4, 8, 24, 36, 44 6 : Baseline to weeks 2, 4, 8, 12, 24, 36, 52 7 : Baseline to weeks 2, 4, 8, 12, 24, 36, 44, 52 10, 11, 12 : Baseline through week 64 | — |
Countries
Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, Chile, Colombia, Czechia, Czech Republic, France, Germany, Greece, Hungary, Latvia, Lithuania, Mexico, Netherlands, Peru, Poland, Portugal, Romania, Russian Federation, Serbia, Slovakia, South Africa, Spain, Ukraine, United Kingdom, United States
Outcome results
None listed